EP 1001973 A1 20000524 - COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4
Title (en)
COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4
Title (de)
VERBINDUNGEN, DIE DIE VLA-4 VERMITTELTE ADHÄSION VON LEUKOZYTEN INHIBIEREN
Title (fr)
COMPOSES INHIBANT L'ADHESION LEUCOCYTAIRE INDUITE PAR VLA-4
Publication
Application
Priority
- US 9815952 W 19980731
- US 90441697 A 19970731
Abstract (en)
[origin: WO9906433A1] Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
IPC 1-7
IPC 8 full level
A61K 31/381 (2006.01); A61K 31/403 (2006.01); A61K 31/404 (2006.01); A61K 31/405 (2006.01); A61K 31/428 (2006.01); C07D 333/20 (2006.01); A61K 31/4402 (2006.01); A61K 31/4406 (2006.01); A61K 31/4409 (2006.01); A61K 31/4439 (2006.01); A61K 31/472 (2006.01); A61K 38/00 (2006.01); A61P 1/00 (2006.01); A61P 3/10 (2006.01); A61P 9/10 (2006.01); A61P 11/00 (2006.01); A61P 11/06 (2006.01); A61P 13/12 (2006.01); A61P 17/00 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 25/28 (2006.01); A61P 27/02 (2006.01); A61P 29/00 (2006.01); A61P 35/04 (2006.01); A61P 43/00 (2006.01); C07D 209/20 (2006.01); C07D 213/55 (2006.01); C07D 217/26 (2006.01); C07D 277/80 (2006.01); C07D 417/14 (2006.01); C07K 5/06 (2006.01); C07K 5/062 (2006.01); C07K 5/065 (2006.01); C07K 5/072 (2006.01); C07K 5/078 (2006.01)
CPC (source: EP KR)
A61P 1/00 (2018.01 - EP); A61P 3/10 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 11/00 (2018.01 - EP); A61P 11/06 (2018.01 - EP); A61P 13/12 (2018.01 - EP); A61P 17/00 (2018.01 - EP); A61P 17/06 (2018.01 - EP); A61P 19/02 (2018.01 - EP); A61P 25/28 (2018.01 - EP); A61P 27/02 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 35/04 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07K 5/06017 (2013.01 - KR); C07K 5/06026 (2013.01 - EP); C07K 5/0606 (2013.01 - EP); C07K 5/06078 (2013.01 - EP); C07K 5/06113 (2013.01 - EP); C07K 5/06139 (2013.01 - EP); A61K 38/00 (2013.01 - EP)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9906433 A1 19990211; AU 8678698 A 19990222; BR 9811569 A 20000919; CA 2290746 A1 19990211; CN 1265669 A 20000906; EP 1001973 A1 20000524; HU P0004529 A2 20010428; HU P0004529 A3 20010528; IL 133641 A0 20010430; JP 2001512136 A 20010821; KR 20010022423 A 20010315; NO 20000451 D0 20000128; NO 20000451 L 20000323; PL 338506 A1 20001106
DOCDB simple family (application)
US 9815952 W 19980731; AU 8678698 A 19980731; BR 9811569 A 19980731; CA 2290746 A 19980731; CN 98807765 A 19980731; EP 98938207 A 19980731; HU P0004529 A 19980731; IL 13364198 A 19980731; JP 2000505188 A 19980731; KR 20007001005 A 20000129; NO 20000451 A 20000128; PL 33850698 A 19980731